Basilea Pharmaceutica
BSLN.SWBSLN.SW · Stock Price
Historical price data
Overview
Basilea Pharmaceutica is a profitable, Swiss-based biopharma company dedicated to becoming a leading global anti-infectives company. Its mission is to address the critical unmet medical need in severe infections through the commercialization of its two marketed products, Cresemba and Zevtera, and the development of a targeted pipeline of novel antibiotics and antifungals. The company's strategy leverages deep expertise in anti-infective development, regulatory navigation, and global commercialization, supported by a disciplined operational focus and strategic partnerships with entities like BARDA.
Technology Platform
A specialized anti-infective development and commercialization platform built on deep scientific expertise in pathogen biology, excellence in clinical development for severe infections, and proven regulatory and global commercialization capabilities.
Pipeline
54| Drug | Indication | Stage | Watch |
|---|---|---|---|
| alitretinoin | Hand Dermatoses | Phase 3 | |
| ceftobiprole medocaril + vancomycin+aztreonam | Acute Bacterial Skin and Skin Structure Infections | Phase 3 | |
| alitretinoin | Eczema | Phase 3 | |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Pl... | Candidemia | Phase 3 | |
| ceftobiprole medocaril + Vancomycin plus Ceftazidime | Skin Diseases, Infectious | Phase 3 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Basilea competes in specialized hospital anti-infective markets against large pharma companies like Pfizer, Merck, and Gilead. Its differentiation lies in its focused expertise, the broad-spectrum profiles of its agents, and its successful navigation of regulatory pathways. Government partnerships, like with BARDA, provide a unique competitive and financial advantage.
Company Timeline
Founded in Basel, Switzerland
IPO — $200.0M
Debt: $100.0M
PIPE: $75.0M